Ex­clu­sive: Af­ter Covid piv­ot, biotech nabs funds to be first in the clin­ic with a non-hor­mon­al con­tra­cep­tive for men

The goal was to cre­ate a non-hor­mon­al con­tra­cep­tive that women could take to pre­vent preg­nan­cy and po­ten­tial­ly STIs, but the Covid-19 pan­dem­ic caused Your­Choice Ther­a­peu­tics to change course and even­tu­al­ly fo­cus most ef­forts on a non-hor­mon­al pill for men.

With Se­ries A fund­ing and a pre-IND meet­ing with the FDA un­der its belt, the biotech ex­pects to be the first com­pa­ny to en­ter the clin­ic with an in­ves­ti­ga­tion­al non-hor­mon­al con­tra­cep­tive for sperm-pro­duc­ers, with the goal of lim­it­ing sperm counts to in­fer­tile lev­els. A healthy vol­un­teer study in the US, if green­lit by the agency, will be­gin in the first half of next year, CEO Akash Bak­shi tells End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER